Background Pharmacokinetic non-inferiority of subcutaneous (SC) to intravenous (IV) CT-
P13 maintenance therapy was demonstrated in a randomized trial (NCT02883452). This …

We read with interest the recently published REMSWITCH study by Buisson et al. 1 The
authors report a large, multicenter cohort study evaluating clinical and pharmacologic …

Background & Aims CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV)
infliximab biosimilar CT-P13 IV, creates a unique exposure profile. We aimed to demonstrate …

Abstract Background and Aims We assessed the effectiveness of switching from intravenous
to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with …

Background The long‐term risk of relapse after switching from intravenous (IV) to
subcutaneous (SC) infliximab remains unknown in inflammatory bowel disease (IBD). Aims …

Background Intravenous [IV] infliximab is a well-established therapy for inflammatory bowel
diseases [IBD] patients. A subcutaneous [SC] formulation of infliximab [CT-P13] has recently …

Abstract Background and Objective Whether benefits and risks of intravenous (IV) infliximab
combotherapy with immunosuppressants versus infliximab monotherapy apply to …

Background & aims This study compared pharmacokinetics, symptomatic and endoscopic
efficacy, safety, and immunogenicity of a subcutaneous formulation of the infliximab …

Background A new subcutaneous (SC) formulation exists for infliximab (CT-P13 SC). The
aim of this study was to assess the durability of clinical and endoscopic responses after a …

Background Studies on elective switching to the subcutaneous (SC) formulation of infliximab
revealed comparable efficacy and safety and higher infliximab level than those exhibited by …